BCG无应答非肌层浸润性膀胱癌临床试验治疗时机方案的影响评估
该研究回顾性分析 tertiary referral center 中接受膀胱保留治疗的 BCG 无应答 NMIBC 患者,评估常用临床试验治疗时间截点(30、60、90 天)对肿瘤学结局的影响。结果显示不同时间截点的无进展生存期相似(均 p > 0.05),多变量分析支持该结果,提示基于治疗时间的入组标准可能可以放宽。
要点
- 30、60、90 天治疗时间截点间无进展生存期相似(均 p > 0.05)。
- 多变量 Cox 回归调整 BST 类型后结果一致。
- 基于治疗时间的入组标准可能可以扩展,避免领先时间排除。
核心结论
- 基于治疗时间的临床试验入组标准可能可以扩展,使更多患者参与试验并避免领先时间排除。
研究设计与样本
- 回顾性审查三级转诊中心接受膀胱保留治疗的 BCG 无应答 NMIBC 患者数据。
- 采用 Kaplan-Meier 分析和多变量 Cox 回归分析,治疗时间作为连续变量。
主要发现
- 使用 30 天、60 天和 90 天截点时无进展生存期相似(均 p > 0.05)。
- 多变量分析调整 BST 类型后结果得到证实。
- 次要终点包括无膀胱切除术生存期和总生存期在各治疗时间区间相当(均 p > 0.05),多变量分析支持。
关键数值与推荐
- 目前大多数 BCG 无应答膀胱保留试验要求组织病理学确认后 60-90 天内开始治疗。
- 30 天、60 天、90 天治疗时间截点间无进展生存期差异均无统计学意义(均 p > 0.05)。
临床怎么用
- 对于不适合或拒绝根治性膀胱切除术的 BCG 无应答 NMIBC 患者,膀胱保留治疗时机选择可参考试验时间窗口的放宽趋势。
- 临床 trial 设计时可考虑扩展基于治疗时间的入组标准,以减少领先时间偏倚导致的排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with bacillus Calmette-Guérin (BCG)-unresponsive (UR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy may pursue bladder-sparing therapy (BST). Currently, most BST trials in the BCG-UR setting mandate treatment initiation within 60-90 d of histopathologic confirmation. Given the lack of data on optimal treatment windows, we evaluated whether these time restrictions have oncologic merit. We retrospectively reviewed data for patients with BCG-UR NMIBC treated with BST at a tertiary referral center. Commonly used clinical trial cutoffs for time to treatment were assessed using Kaplan-Meier analysis. Multivariable Cox regression analysis was also performed, with time to treatment included as a continuous variable. Progression-free survival (PFS) was the primary endpoint, defined as progression to muscle-invasive disease or metastasis. Similar PFS was observed when using 30-d, 60-d, and 90-d cutoffs (all p > 0.05). These results were corroborated on multivariable analysis with adjustment for BST type. Secondary endpoints, including cystectomy-free survival and overall survival, were comparable across time-to-treatment intervals (all p > 0.05), with findings supported by multivariable analyses. These results indicate that inclusion criteria based on time to treatment can probably be expanded, which would allow more patients to participate in clinical trials by avoiding leadtime exclusion.
引用
- Guske C, Jazayeri SB, Harrs C, et al. Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025. PMID: 40670271. doi:10.1016/j.euo.2025.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。